Enterome to present at upcoming investor conferences
Paris, France – July 1, 2021
ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, today announces that Pierre Belichard, CEO, will present an overview of the Company and take part in 1-on-1 meetings with institutional investors at the following conferences:
- BTIG Virtual Biotechnology Conference: August 9-10
- C. Wainwright 23rd Annual Global Investment Conference: September 13-14
Download the press release (.pdf format)